TS
SNDX icon

Thomas Steyer’s Syndax Pharmaceuticals SNDX Stock Holding History

Thomas Steyer’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$234K – 171
2026
Q1 		$234K Hold
10,000
– – ﹤0.01% 133
2025
Q4 		$210K Hold
10,000
– – ﹤0.01% 134
2025
Q3 		$154K Hold
10,000
– – ﹤0.01% 129
2025
Q2 		$93.7K Hold
10,000
– – ﹤0.01% 132
2025
Q1 		$123K Hold
10,000
– – ﹤0.01% 132
2024
Q4 		$132K Hold
10,000
– – ﹤0.01% 140
2024
Q3 		$193K Hold
10,000
– – ﹤0.01% 144
2024
Q2 		$205K Hold
10,000
– – ﹤0.01% 136
2024
Q1 		$238K Hold
10,000
– – ﹤0.01% 139
2023
Q4 		$216K Buy
+10,000
New +$154K ﹤0.01% 126

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Thomas Steyer's SNDX Position: Q2 2026 in Review

Thomas Steyer sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 10,000 shares — an estimated $234K sold.

Thomas Steyer first reported a position in SNDX in Q4 2023 and held it in 10 quarters. The position peaked at $238K in Q1 2024. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Thomas Steyer reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 10,000 Syndax Pharmaceuticals shares in Q2 2026, an estimated $234K.
  • Thomas Steyer first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Thomas Steyer's Syndax Pharmaceuticals position peaked at $238K in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.